Background- Candida auris is an emerging multidrug-resistant (MDR) fungal pathogen that poses a significant global health threat, particularly in healthcare settings. Its ability to cause invasive infections, coupled with its resistance to multiple antifungal drugs and propensity for hospital outbreaks, necessitates rapid and accurate diagnostic and control strategies. Aim- This report aims to comprehensively review the biotechnological approaches employed in the rapid detection, effective control, and proactive prevention of C. auris infections. A particular focus will be placed on CRISPR-based diagnostic methods and novel biotechnological interventions for managing this formidable pathogen. Methodology- Conventional diagnostic methods for C. auris often suffer from limitations such as prolonged turnaround times and misidentification issues. The advent of molecular diagnostics, including PCR, sequencing, and MALDI-TOF, has significantly improved detection capabilities. Among these, CRISPR technology has emerged as a highly promising tool for rapid, sensitive, and specific C. auris detection. Systems like SHERLOCK and DETECTR, utilizing Cas12 and Cas13 enzymes, offer point-of-care potential and the ability to detect resistance genes. Beyond diagnostics, biotechnological strategies for control and prevention involve the development of novel antifungal compounds, nanotechnology-based solutions such as antifungal coatings and targeted nanoparticles, and CRISPR-based gene editing for identifying therapeutic targets. These innovations are crucial for mitigating the spread and impact of C. auris. Conclusion- CRISPR-based diagnostic approaches represent a significant advancement in the rapid and accurate identification of C. auris, facilitating timely intervention and outbreak control. Coupled with other biotechnological innovations in prevention and control, these strategies are poised to revolutionize the management of this challenging fungal pathogen, ultimately improving patient outcomes and public health safety.